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DYT1 dystonia, an early onset generalized dystonia, also
known as Oppenheim’s dystonia, is an inherited isolated
dystonia characterized by progressive generalized muscle
spasms and sustained postures leading to significant disabil-
ity [1]. The disease is inherited in an autosomal dominant
manner with incomplete penetrance (30–40 %) and typic-
ally presents in childhood [2]. Patients harbor a 3-bp
(GAG) deletion in the coding region of the TOR1A gene on
chromosome 9q34 that encodes the protein torsinA [3].
This deletion corresponds to loss of a single glutamate at
amino acid residue 302 or 303 (torsinA ΔE) [4]. The func-
tion of wildtype torsinA has been speculative, but relatively
recent studies have demonstrated its involvement in protein
trafficking, quality control, secretion, and degradation (for
review, see Dauer 2014 [5]). The pathogenic mechanism
leading to disease as a result of this deletion is thought to
likely involve disruption of sensorimotor circuit develop-
ment and function [6]. Recent evidence also suggests stri-
atal cholinergic dysfunction, or dysregulation, as a potential
mechanism underlying the pathophysiology of DYT1 dys-
tonia [7].
Various in vitro and transgenic animal models of DYT1
dystonia have demonstrated altered cell morphology and
nuclear changes at the light microscopic level, including
torsinA accumulation and torsinA-positive inclusions in
the brainstem (see Dauer 2014 [5] and Oleas et al. 2013
[8] for review of cell culture and animal model findings,
respectively). Contrary to findings in animal tissues, no
consistent or specific histopathologic changes have been
noted in postmortem neuropathologic studies of patients
with DYT1 dystonia (Table 1). Subcellular changes (e.g.,
inclusions) in DYT1 brains have been described in a small
human postmortem study [9], but their specificity remains
controversial. That study reported the presence of peri-
nuclear and intranuclear inclusion bodies and protein
accumulation in neurons that were immunoreactive for
torsinA and ubiquitin, and co-localized with choline ace-
tyltransferase (ChAT) and a nuclear envelope marker,
lamin A/C, in the midbrain and pontine reticular forma-
tion (pedunculopontine nucleus (PPN), cuneiform nucleus
(CN), and periaqueductal grey (PAG)); these changes were
notably absent in controls. A more recent study, however,
failed to confirm the presence of immunoreactive inclu-
sions in human DYT1 dystonia brain tissue (using anti-
bodies to ubiquitin and p62) [10]. Additionally, two earlier
studies failed to reveal inclusion bodies, aggregates, or ab-
errant staining for torsinA in DYT1 brains and in other
dystonia (non-DYT1) cases [11, 12].
Here, we sought to analyze genetically confirmed DYT1
brain specimens with antibodies to torsinA, ubiquitin pro-
tein conjugate (UPC), and ChAT in an attempt to identify
the previously reported intracellular immunoreactive pro-
tein inclusions/aggregates in the midbrain as well as in
other cholinergic nuclei, including the striatum. Our study
included six brain samples from DYT1 patients (mean age
83.0 ± 9.1 years; all female), procured from the University of
Maryland Brain and Tissue Bank (BTB); demographic and
autopsy data from four of our DYT1 subjects matched
those reported previously [10] and most likely represent tis-
sue from the same subjects. In our study, three patients
were clinically symptomatic and the remaining were non-
manifesting carriers of the DYT1 mutation. Control brain
tissue samples from seven subjects without clinical evi-
dence of dystonia or other movement disorders were
matched for age and sex (mean age 83.4 ± 8.0 years; all fe-
male). Formalin-fixed paraffin-embedded (FFPE) tissue
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sections from the striatum, motor and sensory cortices in
all patients and controls, and from the brainstem (mid-
brain/pons, including PPN, CN, and PAG) in five of six
DYT1 cases and all controls were evaluated. Routine
hematoxylin-eosin staining was unrevealing. Immunohisto-
chemistry (IHC) with antibodies directed to the following
antigens were used: torsinA (Chemicon, MAB5550), ChAT
(Millipore, AB144P), and ubiquitin protein conjugate (Milli-
pore, 09–408). Additionally, IHC with anti-beta amyloid
(Dako, M0872), anti-phospho-tau (AT8, Pierce, MN1020),
and anti-alpha synuclein (Cell Signaling, 2647) antibodies
along with Bielschowsky silver staining excluded significant
neurodegenerative disease. Double staining IHC was per-
formed for torsinA and ChAT using an automated immu-
nostainer (Leica Bond-Max, Buffalo Grove, IL). Western
blot analysis was performed with anti-torsinA on fresh-
frozen control human brain tissue lysates and appropriate
molecular weight labeling for the torsinA protein (37 kDa)
was confirmed (Fig. 1). To further evaluate intracellular
chromogen (3,3-diaminobenzidine and Fast Red)
localization, multispectral imaging (CRi Nuance V.2.8,
Woburn, MA) was employed on double-labeled fixed tissue
stained with torsinA and ChAT.
No specific cytoplasmic, perinuclear, or intranuclear
torsinA-immunoreactive inclusions were identified in
our DYT1 tissues. Immunoreactivity for torsinA, ChAT,
and UPC in both DYT1 and control groups yielded
similar results and predominantly showed normal stain-
ing patterns for these endogenous cellular proteins. In
both groups, torsinA demonstrated granular cytoplas-
mic staining in all regions evaluated, as well as punctate
immunoreactivity in the neuropil (Fig. 2a). In addition
to its widespread neuroanatomic distribution, cellular
localization studies have shown that wildtype torsinA is
limited to neuronal cytoplasm (endoplasmic reticulum),
nuclear envelope, and processes. It should be noted that
occasional variations in the staining pattern of torsinA
were seen in both DYT1 and control tissues. Apparent
cytoplasmic aggregation of the torsinA protein was seen
in both groups, with these changes most prominent in
large striatal cholinergic interneurons (Fig. 2b, c, d).
Table 1 DYT1 dystonia neuropathology studies
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AA residues 299–312; mouse monoclonal
D-MG10: AA residues 208–249)
Cytoplasm, dendrites, and axons in both DYT1











AA residues 323–332), Anti-ubiquitin,
Anti-UPC, Anti-ChAT









No Anti-ubiquitin, Anti-p62 N/A
AA amino acid, ChAT choline acetyl transferase, UPC ubiquitin-protein conjugate
Fig. 1 Specificity of the torsinA antibody MAB5550 by Western blot
analysis. This Western blot of two control human brain homogenates
(labeled as S1 and S2) was performed with anti-torsinA and anti-actin
primary antibodies. The location and corresponding molecular weight
for torsinA (37 kDa) is shown. Actin (42 kDa) was used as a
loading control
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Inclusion body-like immunoreactivity seen in a control
subject (Fig. 2e) exemplifies the non-specific nature of
these changes. Occasional neurons in the striatum in two
DYT1 patients demonstrated perinuclear accumulation or
accentuation of torsinA (Fig. 2f, g); this change was rare
and not seen in control tissue. The staining patterns and
distribution for ChAT and UPC were similar between both
groups. ChAT showed diffuse expression in neuronal cell
bodies and processes, while UPC demonstrated predomin-
antly cytoplasmic immunoreactivity without evidence of
inclusion bodies in the aforementioned brain regions.
Our results add to the growing body of evidence that
there are no consistent torsinA immunoreactive protein in-
clusions associated with, or specific to, DYT1 dystonia in
humans. In cell culture studies of neural cells transfected
with mutant torsinA, cells demonstrated large perikaryal in-
clusions ultrastructurally composed of spheroid whorled
membranes [13]. The location of the collections appeared
to be mutation status-related, with overexpression of mu-
tant torsinA forming inclusions adjacent to the nuclear
membrane and overexpressed wildtype protein aggregating
within the cytoplasm. This latter feature is in keeping with
our findings but was nonspecific and may possibly repre-
sent a response of wildtype torsinA to cellular stress (e.g.,
agonal state). The perinuclear accentuation of torsinA im-
munoreactivity we observed has previously been described
in cultured cells exposed to oxidative stress [14]. Lastly, it
has been suggested that endogenous torsinA levels may be
lower in vivo as compared to those in transfected cells due
to overexpression in cell culture models, which may affect
subcellular localization of torsinA [15].
Potential reasons for recurrent failure to demonstrate in-
clusions in human DYT1 tissue have been noted [5, 10, 12]
and deserve mention here. Foremost, DYT1 dystonia is
rare and tissue availability for sufficient sample size analysis
is very limited; this is a limitation in the context of an in-
completely penetrant disease, as disease-specific changes
may be related to clinically apparent disease. Notably, while
our evaluation was already limited to six DYT1 patients,
only five included brainstem tissue (including the PPN,
CN, and PAG) for evaluation. Second, studies involving
human and animal tissues have failed to recapitulate the
Fig. 2 Cellular distribution of torsinA and ChAT in DYT1 and control striatum. a Normal staining pattern and cellular distribution of torsinA in the
human striatum (scale bar, 20 μm). TorsinA shows granular cytoplasmic staining (inset, arrowheads; scale bar, 10 μm). b, c, d Fluorescence-like
multispectral image (gated immunohistochemical chromogen signal) of torsinA protein (red) reveals circumscribed collections in the cytoplasm of
both DYT1 and control neurons (arrowheads; scale bars, 20 μm). ChAT (green) shows diffuse immunoreactivity within the cytoplasm and processes in
both DYT1 and controls. e This section of an unaffected control shows an inclusion-like aggregate immunoreactive to torsinA (red) (scale bar, 20 μm).
f, g Also identified was perinuclear accumulation of torsinA (red) seen in DYT1 tissue, thought to be a response to cellular stress (scale bars, 20 μm)
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immunoreactive protein aggregates observed in culture
cells overexpressing torsinA (see Dauer [5] for review),
supporting the suspected lack of neurodegeneration in the
disease. The human tissue studies that failed to identify
torsinA inclusions used various anti-torsinA antibodies
directed against different epitopes, which further supports
that lack of inclusion body formation in DYT1 dystonia.
Furthermore, there is strong evidence linking altered
cholinergic striatal function, and its inputs from other
structures such as the brainstem, cerebellum and thalamus,
to the underlying pathophysiology in DYT1 dystonia (for
review see Eskow Jaunarajs et al. [16]). Indeed, postmortem
analyses of the putamen of DYT1 subjects have shown
decreased levels of cholinergic markers [7].
In conclusion, there is little evidence supporting the
presence of specific cellular morphologic changes in
DYT1 dystonia at the light microscopic level in human
tissue. The significance and specificity of the changes we
observed are best addressed with larger postmortem
studies combining histopathology and disease-specific
cell models, such as patient-specific induced pluripotent
stem cells (iPSCs). Use of iPSC-derived neurons would
allow the subcellular localization of torsinA, and any in-
clusions, to be explored in living cells without altering
the level of torsinA expression.
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